A cannabinoid drug company has opted to undertake its trials in America due to the complexities of the UK’s licensing regime.
The same understaffed Government department that issues farmers shotgun permits to kill crows is also responsible for analysing 10,000-page medical cannabis trial submissions.
And, a new report is calling on the UK’s recently-electedLabour Government to amend the regulations and end this administrative ‘nightmare’.
Speaking at an on-line conference examining the mis-firing UK medical cannabis research landscape, Dr Andy Yates, Chief Scientific Officer at Artelo Biosciences, elaborated on the industry’s frustrations.
Problems In The UK
He explained how it is currently working on trials for three synthetic cannabis drugs: “Our second drug, which is a modifier of the human endocannabinoid system is the one where we are actually taking our clinical trials to the US.
“This is simply because we have had so many problems here in the UK. I do believe that is a loss for UK plc…and the US will get the subsequent studies…this is a great shame for endocannabinoid science in the UK.”
